Scientific Rationale for Waiving Clinical Efficacy Testing of Biosimilars
Sarfaraz Niazi Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois, Chicago, IL, USACorrespondence: Sarfaraz Niazi, Email niazi@niazi.comAbstract: After 18 years and the administration of billions of doses, there is little doubt about biosimilars’ safety and efficacy....
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2022-08-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/scientific-rationale-for-waiving-clinical-efficacy-testing-of-biosimil-peer-reviewed-fulltext-article-DDDT |